Trizivir (AZT/3TC/Abacavir)
| Brand Name: |
Trizivir |
| Generic Name: |
Zidovudine/ lamivudine/ abacavir, AZT/3TC/ABC |
| Adult Single Dose: |
One tablet containing 300 mg AZT,
150 mg 3TC and 300 mg ABC (twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- Trizivir (Zidovudine + Lamivudine + Abacavir) (November 14, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Trizivir (AZT/3TC/Abacavir) (September 13, 2012)
From AIDSinfo
- Trizivir (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Trizivir (AZT/3TC/Abacavir) (PDF) (November 2011)
From ViiV Healthcare
- Trizivir (AZT + Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Trizivir (AZT/3TC/Abacavir) (August 15, 2006)
From AIDS Treatment Data Network
- Drug Interactions: Trizivir (August 2004)
From Project Inform
- EU Approves GlaxoSmithKline's HIV Triple Therapy Trizivir (January 4, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approves Videx EC and Trizivir (November 27, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- "Trizivir" Approved: Three Existing Drugs in One (November 17, 2000)
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Trizivir for HIV (November 15, 2000)
From U.S. Food and Drug Administration
Research
- The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from TheBodyPRO.com
- A5095 and the Triple-Nucleoside Saga (January 2005)
A second look at the study that -- at the time -- appeared to doom Trizivir; part of HIV JournalView's Top 10 Research Reports of 2004.
In AIDS Treatment News, from TheBodyPRO.com
- Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- Keeping It Real: Don't Believe Everything You Read (October 2003)
Do the recently revealed limitations of Trizivir make it "dangerous"?.
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
